Using a Dopamine Genetic Risk Score to Predict Impulse Control Behaviours for Parkinson’s Disease Patients
Objective: The current study aimed to utilise a dopamine genetic risk score and objective laboratory-based behavioural measures of impulse control to identify Parkinson’s patients most…Distinct oscillatory fingerprints in dyskinesias mediated by D1 versus D2 receptors
Objective: To characterize the patterns of cortico-basal ganglia oscillations induced by D1 or D2 receptor agonists in a rat model of L-DOPA-induced dyskinesia. Background: In…Deterioration in oral health status potentially associated with apomorphine pump initiation: a case report
Objective: To describe the case of a patient with Parkinson’s disease (PD) who suffered from a rapid deterioration of his oral health status following treatment…Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?
Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…Claims Data Analysis of Parkinson’s Disease Medication Utilization
Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…Epidemiology of Impulse Control Disorders and Association with Dopamine Agonist Exposure in the United States Military
Objective: Evaluate the epidemiology of impulse control disorders in the US Military and their association with dopamine agonist exposure. Background: Impulse control disorders (ICDs) are…Frequency and risk factors of dopamine agonist-induced peripheral edema in patients with Parkinson’s disease
Objective: To determine the frequency and risk factors of peripheral edema (PE) development and whether discontinuation of the drug is enough for treatment. To determine…Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson’s disease: A prospective analysis of Thai Apomorphine Registry
Objective: To evaluate a reduction of LED in PD patients who achieve satisfactory motor control with long-term continuous subcutaneous apomorphine infusion (CSAI) Background: Apomorphine is…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 13
- Next Page »